Search research articles
Contact Us
Filters
Showing results (41-50 of 1,315) with videos related to
Page
of 132
Sort By:
Blood Cancer Journal
|
November 4, 2017
The availability of jobs in the biopharmaceutical industry is 45-fold greater for hematology oncology than medical specialties
V Kaestner, V Prasad
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 5, 2019
Making adjuvant therapy decisions with uncertain data
B Gyawali, V Prasad
The Journal of Dairy Research
|
August 1, 1997
Effect of yogurt and bifidus yogurt fortified with skim milk powder, condensed whey and lactose-hydrolysed condensed whey on serum cholesterol and triacylglycerol levels in rats
A Beena, V Prasad
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 13, 2018
When is crossover desirable in cancer drug trials and when is it problematic?
A Haslam, V Prasad
Bulletin of the Indian Institute of History of Medicine (Hyderabad)
|
March 6, 2007
Medico - historical study of "Visŭcikă" (Cholera)
P V V Prasad
The International Journal of Neuroscience
|
October 1, 1992
Hemispheric priming: effect of response mode on a position replication task
J Cochran, V Prasad
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 9, 2023
Costs per event averted in the neoadjuvant and adjuvant settings of early triple-negative breast cancer
T Olivier, V Prasad
Blood Cancer Journal
|
October 11, 2017
Job postings for biopharmaceutical industry in medical journals is 45-fold greater for hematology oncology than medical specialties
V Kaestner, V Prasad
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 19, 2020
When are randomized controlled trials needed to assess novel anticancer drugs? An illustration based on the development of selpercatinib, a RET inhibitor
J Gill, V Prasad
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 11, 2020
The FDA approval of pembrolizumab for patients with TMB >10 mut/Mb: was it a wise decision? No
V Prasad, A Addeo
Page
of 132
Search research articles
Search
Showing results (41-50 of 1,315) with videos related to
Sort By:
Page
of 132
Blood Cancer Journal
|
November 4, 2017
The availability of jobs in the biopharmaceutical industry is 45-fold greater for hematology oncology than medical specialties
V Kaestner, V Prasad
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 5, 2019
Making adjuvant therapy decisions with uncertain data
B Gyawali, V Prasad
The Journal of Dairy Research
|
August 1, 1997
Effect of yogurt and bifidus yogurt fortified with skim milk powder, condensed whey and lactose-hydrolysed condensed whey on serum cholesterol and triacylglycerol levels in rats
A Beena, V Prasad
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 13, 2018
When is crossover desirable in cancer drug trials and when is it problematic?
A Haslam, V Prasad
Bulletin of the Indian Institute of History of Medicine (Hyderabad)
|
March 6, 2007
Medico - historical study of "Visŭcikă" (Cholera)
P V V Prasad
The International Journal of Neuroscience
|
October 1, 1992
Hemispheric priming: effect of response mode on a position replication task
J Cochran, V Prasad
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 9, 2023
Costs per event averted in the neoadjuvant and adjuvant settings of early triple-negative breast cancer
T Olivier, V Prasad
Blood Cancer Journal
|
October 11, 2017
Job postings for biopharmaceutical industry in medical journals is 45-fold greater for hematology oncology than medical specialties
V Kaestner, V Prasad
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 19, 2020
When are randomized controlled trials needed to assess novel anticancer drugs? An illustration based on the development of selpercatinib, a RET inhibitor
J Gill, V Prasad
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 11, 2020
The FDA approval of pembrolizumab for patients with TMB >10 mut/Mb: was it a wise decision? No
V Prasad, A Addeo
Page
of 132